Alto Neuroscience (NYSE:ANRO) Shares Gap Down Following Analyst Downgrade

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price gapped down before the market opened on Thursday after Robert W. Baird lowered their price target on the stock from $41.00 to $38.00. The stock had previously closed at $23.41, but opened at $20.00. Robert W. Baird currently has an outperform rating on the stock. Alto Neuroscience shares last traded at $21.4550, with a volume of 89,945 shares.

A number of other equities analysts have also recently commented on the company. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Thursday. Finally, Wedbush decreased their target price on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in ANRO. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $62,000. Balyasny Asset Management L.P. bought a new position in Alto Neuroscience during the 4th quarter worth $198,000. OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience during the 4th quarter worth $221,000. Vanguard Personalized Indexing Management LLC raised its holdings in Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Alto Neuroscience in the 4th quarter valued at $304,000.

Alto Neuroscience Trading Down 7.9%

The business has a 50-day moving average price of $19.18 and a two-hundred day moving average price of $14.68. The stock has a market capitalization of $689.03 million, a P/E ratio of -9.89 and a beta of 2.01. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.